Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir

Inclusion Criteria: * HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. A second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test or a previous detectable HIV RNA level * HIV RNA level below the limit of quantification of the viral load assay in use in-country within the last 12 months * Screening HIV RNA level below the limit of quantification as defined by the local assay * At least twelve months of stable first-line antiretroviral therapy consisting of nevirapine and 2 nRTIs approved by the Rwandan HIV Treatment guidelines. (No prior changes in ART are allowed) * Enrolled in the Rwanda National ART Program with no in-country transfer within the program. * Negative TB symptom screen or eligible based on algorithm outlined in * Laboratory values obtained within 30 days prior to study entry: * Hemoglobin greater than 8.0 g/dL * Platelet count greater than 40,000/mm3 * AST (SGOT), ALT (SGPT), and alkaline phosphatase less than 5 X ULN * Total bilirubin less than 2.5 x ULN * Calculated creatinine clearance greater than 60 mL/min as estimated by the Cockcroft-Gault equation: * Ability to meet the nutritional requirements for rilpivirine; largest meal should consist of at least 400 total kcals and 117 kcals of fat (13 grams) to be assessed at screening. * For women of reproductive potential, negative serum or urine pregnancy test within 4 weeks of initiating study medications and a negative urine pregnancy test at the entry visit prior to randomization. * "Women of reproductive potential" is defined as women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months) and have not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation). * Age greater than18 years. * Ability and willingness of subject to give informed consent. Exclusion Criteria: * History of on-treatment virologic failure (defined as HIV RNA level greater than 200 copies/mL at or after 6 months of antiretroviral therapy) * Any change in prior ART. * Currently breastfeeding. * Active tuberculosis. * Serious illness requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 14 days prior to study entry. * NOTE: Isolated cutaneous Kaposi's Sarcoma, oral candidiasis, vaginal candidiasis, mucocutaneous herpes simplex, and other non-serious illnesses (as judged by the site investigator) have no restriction. * Known allergy/sensitivity to study drugs or their formulations. * Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * Requirement for any current medications that are prohibited with any study treatment.